Biocon Biologics Secures Positive EMA CHMP Opinion for Pertuzumab Biosimilar
Biocon Ltd 路 Press Release 路 21 Sept 2026, 1:58 pm
Biocon Biologics Secures Positive EMA CHMP Opinion for Pertuzumab Biosimilar Biocon Biologics, a wholly owned subsidiary of Biocon Limited, received a positive opinion from the EMA's CHMP on 21st Sep'26 recommending marketing authorization for Pebrilzo (Pertuzumab biosimilar, 420 mg concentrate solution for infusion). The drug targets HER2-positive breast cancer across early, adjuvant, and metastatic stages. Notably, Pebrilzo is the first monoclonal antibody biosimilar recommended under the EMA's tailored clinical development approach based on analytical and pharmacokinetic data. Final European Commission marketing approval remains pending.
Original exchange filing (PDF)
More announcements from Biocon Ltd
- Press Release 路 18 Nov 2026
- Press Release 路 16 Nov 2026
- Intimation on Schedule of Meetings with Analyst(s)/institutional Investor(s) 路 12 Nov 2026
- Earnings Call Transcript for Q2 FY27 路 12 Nov 2026
- Audio and Video Recording of Q2 FY27 Earnings Call 路 05 Nov 2026
- Communication regarding withholding of final dividend for the FY 2025-26 路 04 Nov 2026
- Investor Presentation 路 04 Nov 2026
- Change in Senior Management Personnel 路 04 Nov 2026
